Subcutaneous Furosemide: A Novel to Euvolemia.

Autor:	Cheikhali R; From the Department of Medicine at New York Medical College, Valhalla, NY., Kalish C; Department of Medicine at Westchester Medical Center, Valhalla, NY., Maksymiuk V; Department of Medicine at Westchester Medical Center, Valhalla, NY., Nasereldin M; From the Department of Medicine at New York Medical College, Valhalla, NY., Bahl S; Department of Cardiology at Westchester Medical Center, Valhalla, NY., Frishman WH; From the Department of Medicine at New York Medical College, Valhalla, NY., Aronow WS; Department of Cardiology at Westchester Medical Center, Valhalla, NY., Pan S; Department of Cardiology at Westchester Medical Center, Valhalla, NY.
Jazyk:	angličtina
Zdroj:	Cardiology in review [Cardiol Rev] 2024 Mar 23. Date of Electronic Publication: 2024 Mar 23.
DOI:	10.1097/CRD.0000000000000689
Abstrakt:	Furoscix, a subcutaneous pH-neutral formulation of furosemide, obtained US Food and Drug Administration approval in October 2022 for adult patients with New York Heart Association class II and class III chronic heart failure. This approval marks an anticipated potential shift in the traditional management of decongestive therapy in chronic heart failure patients from the confines of the hospital to more accessible outpatient or home-based care. In this review, we will summarize existing evidence regarding the use of subcutaneous furosemide in comparison to both oral and intravenous formulations, highlighting the demonstrable benefits of its application in both outpatient and inpatient settings, and also discuss several factors that may limit its use. Competing Interests: Disclosure: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu